Semnur Pharmaceuticals, Inc.

Our Company is a late-stage clinical biopharmaceutical company that develops and commercializes innovative non-opioid pain management products for acute and chronic pain. The company focuses on indications with high unmet needs and large market opportunities. Its lead product candidate is SP-102 (10 mg, dexamethasone sodium phosphate viscous gel). If approved, SP-102 is designed to be the first U.S. Food and Drug Administration ("FDA") approved non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica). This formulation contains no preservatives, surfactants, solvents, or particulates and is expected to be available in a pre-filled syringe formulation following FDA approval. Founded in 2013, Our Company has invested in its intellectual property portfolio and infrastructure. It has conducted pharmacokinetic ("PK") and toxicology studies, including a Phase 1 PK bridging study, a Phase 2 repeat dose study, and a pivotal Phase 3 study.